Feasibility and safety of minimized cardiopulmonary bypass in major aortic surgery
Open Access
- 28 June 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 17 (4), 659-663
- https://doi.org/10.1093/icvts/ivt285
Abstract
Conventional cardiopulmonary bypass causes haemodilution and is a trigger of systemic inflammatory reactions, coagulopathy and organ failure. Miniaturized cardiopulmonary bypass has been proposed as a way to reduce these deleterious effects of conventional cardiopulmonary bypass and to promote a more physiological state. The use of miniaturized cardiopulmonary bypass has been reported in low-risk patients undergoing valve and coronary artery bypass graft (CABG) surgery. However, little is known about its application in major aortic surgery. From February 2007 to September 2010, 49 patients underwent major aortic surgery using the Hammersmith miniaturized cardiopulmonary bypass (ECCO, Sorin). Data were extracted from medical records to characterize preoperative comorbidities (EuroSCORE), perioperative complications and the use of blood products. The same data were collected and described for 328 consecutive patients having similar surgery with conventional cardiopulmonary bypass at the Bristol Heart Institute, our twinned centre, during the same period. The miniaturized cardiopulmonary bypass group had a median EuroSCORE of 8 [inter-quartile range (IQR): 5–11], 13% had preoperative renal dysfunction and 20% of operations were classified as emergency or salvage. Thirty-day mortalities were 6.4; and 69, 67 and 74% had ≥1 unit of red cells, fresh frozen plasma (FFP) and platelets transfused, respectively. Eight percent of patients experienced a renal complication, and 8% a neurological complication. The conventional cardiopulmonary bypass group was similar, with a EuroSCORE of 8 (IQR: 6–10); 30-day mortalities were 9.4; and 68, 62 and 74% had ≥1 unit of red cells, FFP and platelets transfused, respectively. The proportions experiencing renal and neurological complications were 14 and 5%. Our experience suggests that miniaturized cardiopulmonary bypass is safe and feasible for use in major aortic cardiac surgery. A randomized trial is needed to evaluate miniaturized cardiopulmonary bypass formally.Keywords
This publication has 10 references indexed in Scilit:
- Neurocognitive outcome after coronary artery bypass surgery using minimal versus conventional extracorporeal circulation: a randomised controlled pilot studyHeart, 2011
- Mini-cardiopulmonary bypass impact on blood conservation strategy in coronary artery bypass graftingInteractive CardioVascular and Thoracic Surgery, 2011
- Aortic valve replacement with minimal extracorporeal circulation versus standard cardiopulmonary bypassInteractive CardioVascular and Thoracic Surgery, 2009
- Meta-analysis of randomised trials comparing the effectiveness of miniaturised versus conventional cardiopulmonary bypass in adult cardiac surgeryHeart, 2009
- Aortic Surgery Using Total Miniaturized Cardiopulmonary BypassThe Annals of Thoracic Surgery, 2008
- Clinical advantages of using mini-bypass systems in terms of blood product use, postoperative bleeding and air entrainment: an in vivo clinical perspective☆European Journal of Cardio-Thoracic Surgery, 2007
- Attenuated Renal and Intestinal Injury After Use of a Mini-Cardiopulmonary Bypass SystemThe Annals of Thoracic Surgery, 2007
- Minimally Invasive Closed Circuit Versus Standard Extracorporeal Circulation for Aortic Valve ReplacementThe Annals of Thoracic Surgery, 2007
- Reduction in blood product usage associated with routine use of mini bypass systems in extracorporeal circulationPerfusion, 2007
- Aortic valve replacement with the minimal extracorporeal circulation (Jostra MECC System) versus standard cardiopulmonary bypass: A randomized prospective trialThe Journal of Thoracic and Cardiovascular Surgery, 2004